- Home
- BJDX vs PRFX Comparison
BJDX vs PRFX Comparison
Compare BJDX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJDX | PRFX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 1.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BJDX | PRFX |
|---|---|---|
| Price | $0.97 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 113.9K | ★ 145.0K |
| Earning Date | 11-07-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.80 |
| 52 Week High | $10.20 | $16.63 |
Technical Indicators
Market Signals| Indicator | BJDX | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 43.64 |
| Support Level | $1.13 | $0.90 |
| Resistance Level | $1.10 | $1.09 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 5.43 | 21.78 |
Price Performance
Historical ComparisonAbout BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.